On the occasion of the UK–France Joint Committee on Science, Innovation and Technology, held at the Ambassade de France au Royaume-Uni on 27–28 May 2026, health and artificial intelligence were identified as two strategic priority areas for collaboration between France and the United Kingdom.
In this context, the Franco-British consortium on biomarkers in psychiatry, a project supported by PEPR PROPSY, is among the selected initiatives.
Its objective is to support research and innovation in order to improve the understanding, prevention, and treatment of five major psychiatric disorders: bipolar disorder, treatment-resistant depression, autism spectrum disorders, and schizophrenia.
To learn more about the consortium, its here.
PEPR PROPSY is proud to contribute to this international initiative, bringing together researchers, clinicians, and partners from both countries around a shared ambition: advancing precision psychiatry through the identification and validation of innovative biomarkers.
Discover the roadmap outlining the shared scientific priorities of this cooperation.